Linked Life Data

19851036

Source:http://linkedlifedata.com/resource/pubmed/id/19851036

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19851036rdf:typepubmed:Citationlld:pubmed
pubmed-article:19851036lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:19851036lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:19851036lifeskim:mentionsumls-concept:C0018213lld:lifeskim
pubmed-article:19851036lifeskim:mentionsumls-concept:C0027021lld:lifeskim
pubmed-article:19851036lifeskim:mentionsumls-concept:C0033511lld:lifeskim
pubmed-article:19851036lifeskim:mentionsumls-concept:C0103647lld:lifeskim
pubmed-article:19851036lifeskim:mentionsumls-concept:C1517942lld:lifeskim
pubmed-article:19851036lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:19851036pubmed:issue1lld:pubmed
pubmed-article:19851036pubmed:dateCreated2010-1-29lld:pubmed
pubmed-article:19851036pubmed:abstractTextPropylthiouracil (PTU) is known to induce myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves disease (GD). Previously, we showed that serum MPO-ANCA were frequently seen in patients with GD treated with PTU. In this study, we analyzed 13 patients with positive MPO-ANCA examining a long-term clinical consequence of these patients as well as antibody titers during 5.6 +/- 3.0 years. PTU therapy was continued in 8 patients and discontinued in 5 patients. Antibody titers decreased in 7 of 8 patients who discontinued PTU therapy but remained positive in 5 patients 5 years after PTU withdrawal. The initial MPO-ANCA levels were significantly higher in those antibody titers remained positive for longer than 5 years (n=5) than in those titers turned to be negative within 5 years after PTU withdrawal (n=3) (203 +/- 256 EU and 22 +/- 2 EU, respectively, P=0.04), but there were no significant differences in age, gender, duration of PTU therapy or dosage of PTU. Among 5 patients who continued PTU therapy, 2 patients with initially low MPO-ANCA titers turned to having negative antibody. No patients had new symptoms or signs of vasculitis throughout the follow-up periods. The long-term follow-up study suggests that higher MPO-ANCA levels remain positive for years after PTU withdrawal but are rarely associated with vasculitis.lld:pubmed
pubmed-article:19851036pubmed:languageenglld:pubmed
pubmed-article:19851036pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19851036pubmed:citationSubsetIMlld:pubmed
pubmed-article:19851036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19851036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19851036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19851036pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19851036pubmed:statusMEDLINElld:pubmed
pubmed-article:19851036pubmed:issn1348-4540lld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:AndoTakaoTlld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:EguchiKatsumi...lld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:AshizawaKiyot...lld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:ImaizumiMisaMlld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:IshiiReikoRlld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:IdeAkaneAlld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:UsaToshiroTlld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:EjimaEriElld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:HorieIchiroIlld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:SeraNobukoNlld:pubmed
pubmed-article:19851036pubmed:authorpubmed-author:UekiIkukoIlld:pubmed
pubmed-article:19851036pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19851036pubmed:volume57lld:pubmed
pubmed-article:19851036pubmed:ownerNLMlld:pubmed
pubmed-article:19851036pubmed:authorsCompleteYlld:pubmed
pubmed-article:19851036pubmed:pagination73-9lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:meshHeadingpubmed-meshheading:19851036...lld:pubmed
pubmed-article:19851036pubmed:year2010lld:pubmed
pubmed-article:19851036pubmed:articleTitleA long-term follow-up of serum myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves disease treated with propylthiouracil.lld:pubmed
pubmed-article:19851036pubmed:affiliationDepartment of Endocrinology and Metabolism, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.lld:pubmed
pubmed-article:19851036pubmed:publicationTypeJournal Articlelld:pubmed